Clinical trials: Squamous-cell Non-Small-cell Lung Cancer
Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications
The primary objectives of this study are to evaluate the safety and tolerability of AMG 794 in adult participants and to determine the optimal biological active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1…
- Conditions
- Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors
- Trial name
- NCT05317078
- Testing
- AMG 794
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 3 people
- Sponsor
- Amgen
Non-small Cell Lung Cancer
Analysis of Soluble Mediators,Cytokines and FACs as Prognostic Factors in Advanced Non-squamous Lung Carcinoma
Recent studies have shown that the assessment of a set of cytokines and / or circulating angiogenic factors (FACs) could be used to identify prognostic factors predictive of efficacy and / or potential mechanisms of resistance to…
- Trial name
- NCT03156868
- Where
- 25 sites in Spain
- Volunteers
- 153 people
- Sponsor
- Spanish Lung Cancer Group
Advanced Solid Tumor, Non-small Cell Lung Cancer
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04795713
- Testing
- MT-6402
- Where
- 16 sites in United States
- Volunteers
- 64 people
- Sponsor
- Molecular Templates, Inc.
Non Small Cell Lung Carcinoma, c-MET
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide.
- Trial name
- NCT06772623
- Testing
- Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab
- Where
- 127 sites in United States, Argentina and 15 more
- Volunteers
- 252 people
- Sponsor
- AbbVie
Metastatic Non-small Cell Lung Cancer (NSCLC), Non-squamous NSCLC
A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
The purpose of this research study is to assess the efficacy and safety of ABP 215 compared to Bevacizumab in Chinese patients with advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT04466917
- Testing
- ABP 215, Bevacizumab, Paclitaxel
- Sponsor
- Amgen
Squamous Non Small Cell Lung Cancer
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
The main purpose of this study is to evaluate if necitumumab added to standard chemotherapy of paclitaxel and carboplatin is more effective to treat cancer than the standard chemotherapy of paclitaxel and carboplatin alone.
- Trial name
- NCT01769391
- Testing
- Necitumumab, Paclitaxel, Carboplatin
- Where
- 51 sites in United States, Germany and 4 more
- Volunteers
- 167 people
- Sponsor
- Eli Lilly and Company
Lung Cancer
Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer
This research studies protein in tumor samples from patients with non-small cell lung cancer. Finding specific proteins in tumor tissue samples from patients with cancer may help doctors tell what type of lung cancer a patient…
- Trial name
- NCT01415739
- Testing
- laboratory biomarker analysis
- Where
- United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)
This randomized comparative study aims to evaluate the satisfaction and quality of life of patients using Cicaplast balm B5, versus Dexeryl, for the management of cutaneous toxicities of iEGFR in squamous cell carcinoma of the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Inhibitor
- Trial name
- CICAFIX (NCT03421912)
- Testing
- Cicaplast Balm B5, Dexeryl
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Centre Leon Berard
Non-Small Cell Lung Cancer
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
The optimal treatment for Stage I or Stage IIA non-small cell lung cancer (NSCLC) remains controversial. Radiographic surveillance alone has been recommended for stage I and stage IIA patients after the tumor is removed…
- Trial name
- NCT01817192
- Testing
- Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
- Where
- 49 sites in United States, France and 1 more
- Volunteers
- 420 people
- Sponsor
- Razor Genomics
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Advanced NSCLC With EGFR Mutation
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
To investigate the survival benefit of first-line therapy for patients with EGFR-sensitive mutation-positive advanced non-squamous non-small cell lung cancer treated with S-1plus gefitinib versus gefitinib monotherapy
- Trial name
- NCT03457337
- Testing
- S-1 plus Gefitinib, Gefitinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer, Unresectable Malignant Neoplasm
Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC
This observational trial is designed to assess the safety profile and tolerability of bevacizumab when combined with chemotherapy as first-line treatment of advanced or recurrent non-squamous NSCLC.
- Trial name
- NCT01963351
- Where
- Greece
- Volunteers
- 150 people
- Sponsor
- University of Athens
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APOLLO (NCT07909031)
- Testing
- CR-002
- Where
- 3 sites in United States
- Volunteers
- 219 people
- Sponsor
- Crescent Biopharma, Inc.
Solid Tumors, Colorectal Cancer
First in Human Study of QLS5316 in Solid Tumors
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of QLS5316, in patients with advanced solid tumors. The study aim to evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and…
- Conditions
- Solid Tumors, Colorectal Cancer, Gastric Cancer or Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT07358884
- Testing
- QLS5316
- Volunteers
- 300 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS…
- Conditions
- Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT04625647
- Testing
- Sotorasib
- Where
- 829 sites in United States, Guam
- Volunteers
- 116 people
- Sponsor
- SWOG Cancer Research Network
Sinonasal Cancer, Squamous Non-small Cell Lung Cancer
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
Background: Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide. These cancers have different causes, with smoking/tobacco exposure and human papilloma virus infection being the most common. .
- Conditions
- Sinonasal Cancer, Squamous Non-small Cell Lung Cancer, Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05879484
- Testing
- pembrolizumab, valemetostat
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Non-small Cell Lung Cancer
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.
- Trial name
- NCT01642004
- Testing
- Nivolumab, Docetaxel
- Where
- 127 sites in United States, Argentina and 19 more
- Volunteers
- 272 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer
Epidermal growth factor receptor Tyrosine kinase inhibitor (EGFR TKI) have been approved to treat NSCLC harboring EGFR mutation as first-line therapy.
- Trial name
- NCT03461185
- Testing
- EGFR-TK Inhibitor, Anti-Angiogenic Drugs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xinqiao Hospital of Chongqing
Gynecologic Cancer, Colorectal Cancer
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05194735
- Testing
- Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Non-Small Cell Lung Cancer
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
This is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum…
- Trial name
- NCT07174908
- Testing
- IN10018 in combination with D-1553, anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed
- Where
- 11 sites in China
- Volunteers
- 400 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.